Immunic (NASDAQ:IMUX) Now Covered by Analysts at StockNews.com
StockNews.com began coverage on shares of Immunic (NASDAQ:IMUX – Free Report) in a research note issued to investors on Thursday. The firm issued a sell rating on the stock. Separately, Wedbush reaffirmed an outperform rating and set a $5.00 price target on shares of Immunic in a research report on Friday, August 4th. View Our […]